Patient characteristics
| . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . |
|---|---|---|---|---|---|---|
| Sex | Male | Female | Female | Male | Male | Male |
| Age, y | 58 | 79 | 51 | 60 | 58 | 66 |
| MM subtype | IgGκ | IgGκ | IgGκ | λLC/BJ | IgGκ | κ LC |
| Prior ASCT | Yes | No | Yes | Yes | Yes | Yes |
| ISS prior to addition of IMiD to Dara | 1 | 2 | 2 | 3 | 1 | 3 |
| Time from diagnosis, y | 11 | 8 | 8 | 6 | 9 | 4.5 |
| Lines of prior therapies | 13 | 8 | 4 | 4 | 3 | 4 |
| Time from last exposure to IMiD to Dara/IMiD (mo) | 13.2 | 16.3 | 20.7 | 15.8 | 37.1 | 13.9 |
| Pomalidomide refractory | Yes, at 4 mg with weekly dexamethasone 40 mg | Yes, at 4 mg with weekly dexamethasone 20 mg and cyclophosphamide 50 | Yes, at 4 mg with weekly dexamethasone 40 mg | No | No | Yes, at 4 mg with weekly dexamethasone 20 mg |
| Lenalidomide refractory | Yes, at 25 mg with weekly dexamethasone 40 mg | Yes, at 25 mg with weekly dexamethasone 40 mg | Yes, at 25 mg with weekly dexamethasone 40 mg | Yes, at 25 mg with weekly dexamethasone 40 mg | Yes, at 25 mg with weekly dexamethasone 40 mg | Yes, at 25 mg with weekly dexamethasone 40 mg |
| Best response to prior and current therapies | ||||||
| Dara monotherapy duration, (mo) | 11 | 17 | 6 | 6 | 10 | 8 |
| Dara-IMiD-DEX | PD | MR | MR | VGPR | PR | VGPR |
| Dara + IMiD PFS, mo | 2 | 3, ongoing | 3, ongoing | 4.5, ongoing | 8, ongoing | 8 |
| . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . |
|---|---|---|---|---|---|---|
| Sex | Male | Female | Female | Male | Male | Male |
| Age, y | 58 | 79 | 51 | 60 | 58 | 66 |
| MM subtype | IgGκ | IgGκ | IgGκ | λLC/BJ | IgGκ | κ LC |
| Prior ASCT | Yes | No | Yes | Yes | Yes | Yes |
| ISS prior to addition of IMiD to Dara | 1 | 2 | 2 | 3 | 1 | 3 |
| Time from diagnosis, y | 11 | 8 | 8 | 6 | 9 | 4.5 |
| Lines of prior therapies | 13 | 8 | 4 | 4 | 3 | 4 |
| Time from last exposure to IMiD to Dara/IMiD (mo) | 13.2 | 16.3 | 20.7 | 15.8 | 37.1 | 13.9 |
| Pomalidomide refractory | Yes, at 4 mg with weekly dexamethasone 40 mg | Yes, at 4 mg with weekly dexamethasone 20 mg and cyclophosphamide 50 | Yes, at 4 mg with weekly dexamethasone 40 mg | No | No | Yes, at 4 mg with weekly dexamethasone 20 mg |
| Lenalidomide refractory | Yes, at 25 mg with weekly dexamethasone 40 mg | Yes, at 25 mg with weekly dexamethasone 40 mg | Yes, at 25 mg with weekly dexamethasone 40 mg | Yes, at 25 mg with weekly dexamethasone 40 mg | Yes, at 25 mg with weekly dexamethasone 40 mg | Yes, at 25 mg with weekly dexamethasone 40 mg |
| Best response to prior and current therapies | ||||||
| Dara monotherapy duration, (mo) | 11 | 17 | 6 | 6 | 10 | 8 |
| Dara-IMiD-DEX | PD | MR | MR | VGPR | PR | VGPR |
| Dara + IMiD PFS, mo | 2 | 3, ongoing | 3, ongoing | 4.5, ongoing | 8, ongoing | 8 |
ASCT, autologous stem cell transplantation; BJ, Bence Jones; BTZ, bortezomib; Dara, daratumumab; IgG, immunoglobulin G; MM, multiple myeloma; PD, progressive disease; PFS, progression-free survival; SD, stable disease; VGPR, very good partial response.